Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/41845
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartin C.A.en
dc.contributor.authorMcgrath B.P.en
dc.date.accessioned2021-05-14T14:21:05Zen
dc.date.available2021-05-14T14:21:05Zen
dc.date.copyright2014en
dc.date.created20140115en
dc.date.issued2014-01-15en
dc.identifier.citationClinical and Experimental Pharmacology and Physiology. 41 (1) (pp 22-29), 2014. Date of Publication: January 2014.en
dc.identifier.issn0305-1870en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/41845en
dc.description.abstractSummary: Numerous studies have examined whether white-coat hypertension (WCHT) is associated with increased cardiovascular risk, but with definitions of WCHT that were not sufficiently robust, results have been inconsistent. The aim of the present review was to standardize the evidence by only including studies that used a definition of WCHT consistent with international guidelines. Published studies were reviewed for data on vascular dysfunction, target organ damage, risk of future sustained hypertension and cardiovascular events. White-coat hypertension has a population prevalence of approximately 15% and is associated with non-smoking and slightly elevated clinic blood pressure. Compared with normotensives, subjects with WCHT are at increased cardiovascular risk due to a higher prevalence of glucose dysregulation, increased left ventricular mass index and increased risk of future diabetes and hypertension. In conclusion, management of a patient with WCHT should focus on cardiovascular risk factors, particularly glucose intolerance, not blood pressure alone. © 2013 Wiley Publishing Asia Pty Ltd.en
dc.languageEnglishen
dc.languageenen
dc.publisherBlackwell Publishing (550 Swanston Street, Carlton South VIC 3053, Australia)en
dc.titleWhite-coat hypertension.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/1440-1681.12114en
dc.publisher.placeAustraliaen
dc.identifier.pubmedid23682974 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23682974]en
dc.identifier.source372024220en
dc.identifier.institution(Martin, Mcgrath) Monash University, Melbourne, VIC., Australia (Martin, Mcgrath) Monash Health, Melbourne, VIC., Australia (Martin) Australian Catholic University, Melbourne, VIC., Australiaen
dc.description.addressB.P. Mcgrath, Monash Doctors Education, Monash Health, Clayton, VIC. 3168, Australia. E-mail: barry.mcgrath@monashen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2014 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCardiovascular risk Glucose intolerance Isolated clinic hypertension White-coat hypertensionen
dc.identifier.authoremailMcgrath B.P.; barry.mcgrath@monashen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
Appears in Collections:Articles
Show simple item record

Page view(s)

22
checked on Feb 7, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.